DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
SGI-1776 is an investigational drug.
There have been 26 clinical trials for SGI-1776. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2017.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, and Leukemia, Myeloid. The leading clinical trial sponsors are Astex Pharmaceuticals, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.
There are two US patents protecting this investigational drug and sixteen international patents.
Recent Clinical Trials for SGI-1776
|Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer||Astex Pharmaceuticals||Phase 1/Phase 2|
|Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer||Bristol-Myers Squibb||Phase 1/Phase 2|
|Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer||National Cancer Institute (NCI)||Phase 1/Phase 2|
Top disease conditions for SGI-1776
Top clinical trial sponsors for SGI-1776
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|SGI-1776||Start Trial||Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors||SuperGen, Inc. (Dublin, CA)||Start Trial|
|SGI-1776||Start Trial||Imidazo[1,2-B]pyridazine and pyrazolo[1 .5-A]pyrimidine derivatives and their use as protein kinase inhibitors||Tolero Pharmaceuticals, Inc. (Salt Lake City, UT)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|